Status:
RECRUITING
Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Autoimmune Diseases
Vasculitis
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this work is to identify, in patients with autoimmune diseases, systemic vasculitis and autoinflammatory disease, cytokine and lymphocyte biomarkers of activity of these diseases to i...
Detailed Description
Autoimmune systemic diseases, systemic vasculitis and autoinflammatory diseases are diseases involving the innate and adaptive immune systems. The pro and anti-inflammatory cytokines, and the T and B ...
Eligibility Criteria
Inclusion
- Patients of 18 years of age or older
- Patients with autoimmune systemic disease, systemic vasculitis or autoinflammatory disease, defined by the international criteria in force for each pathology, among the following:
- Connectivities: lupus, Sjögren syndrome, antiphospholipid syndrome, mixed connectivity and Sharp syndrome, scleroderma, myositis
- Vasculitis of large, small and medium vessels: giant cell arteritis, Takayasu arteritis, Behçet disease, ANCA vasculitis, cryoglobulinemic vasculitis, IgA vasculitis (rheumatoid purpura)
- Buerger's disease (obliterating thromboangitis)
- Granulomatosis and sarcoidosis
- Uveitis
- Monogenic and polygenic autoinflammatory diseases: family Mediterranean fever, TRAPS, CAPS, chronic atrophic polychondritis, pericarditis
- Recurrent fevers and unexplained inflammatory syndromes
- Inflammatory amyloidosis
- Patients affiliated to French social security
Exclusion
- Vulnerable populations:
- Persons deprived of liberty by judicial or administrative decision;
- Persons receiving psychiatric care without their consent;
- Adult subject to a legal protection measure (guardianship, curatorship);
- Persons unable to give their consent.
Key Trial Info
Start Date :
November 29 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 29 2031
Estimated Enrollment :
2250 Patients enrolled
Trial Details
Trial ID
NCT05383339
Start Date
November 29 2022
End Date
November 29 2031
Last Update
July 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Département de Médecine Interne et Immunologie Clinique (DMIIC), Hôpital Pitié-Salpêtrière
Paris, France, France, 75013